(FM) Oncología
Departamento académico
Universitat de Barcelona
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Universitat de Barcelona (27)
2024
-
Access to melanoma drugs in Spain: a cross-sectional survey
Clinical and Translational Oncology
-
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Clinical Cancer Research, Vol. 30, Núm. 8, pp. 1630-1641
-
Prospective study of predictors for anxiety, depression, and somatization in a sample of 1807 cancer patients
Scientific reports, Vol. 14, Núm. 1, pp. 3188
2023
-
SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry
Clinical and Translational Oncology, Vol. 25, Núm. 3, pp. 768-775
2022
-
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121
-
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study
The Lancet Oncology, Vol. 23, Núm. 2, pp. 248-258
-
Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group
Clinical Genitourinary Cancer, Vol. 20, Núm. 4, pp. 388.e1-388.e10
2021
-
Prevalence of nodal involvement in rectal cancer after chemoradiotherapy
The British journal of surgery, Vol. 108, Núm. 10, pp. 1251-1258
2020
-
Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma
Clinical Genitourinary Cancer, Vol. 18, Núm. 6, pp. 452-460
2019
-
Clinical presentation, diagnosis and staging of cholangiocarcinoma
Liver International, Vol. 39, Núm. S1, pp. 98-107
-
Correction to: SEOM clinical guideline for treatment of kidney cancer (2017) (Clinical and Translational Oncology, (2018), 20, 1, (47-56), 10.1007/s12094-017-1765-4)
Clinical and Translational Oncology
-
Triple-drug chemotherapy regimens in combination with an anti-EGFR agent in metastatic colorectal cancer - prospects from phase II clinical trials
Expert Opinion on Investigational Drugs, Vol. 28, Núm. 5, pp. 463-471
2018
-
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types
Annals of Oncology, Vol. 29, Núm. 10, pp. 2121-2128
-
Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer
Expert Opinion on Pharmacotherapy, Vol. 19, Núm. 6, pp. 623-629
-
Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine–erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial)
Cancer Chemotherapy and Pharmacology, Vol. 82, Núm. 6, pp. 935-943
-
SEOM clinical guideline for treatment of kidney cancer (2017)
Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 47-56
-
The safety of ramucirumab for the treatment of colorectal cancer
Expert Opinion on Drug Safety, Vol. 17, Núm. 9, pp. 945-951
2017
-
Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)
European Journal of Endocrinology, Vol. 177, Núm. 4, pp. 309-317
-
Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial
The Lancet Oncology, Vol. 18, Núm. 5, pp. 672-681
2015
-
Spanish Multidisciplinary Melanoma Group (GEM) guidelines for the management of patients with advanced melanoma
European Journal of Dermatology, Vol. 25, Núm. 5, pp. 392-403